SRZNSurrozen, Inc.
Price
+104%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growth fading, the market undecided.
Charts
As reported to the SEC, without any scoring.
Surrozen, Inc. (SRZN) reported revenue of $5.0M in Q2 2026 (quarter ended Jun 30, 2026), up 409% from the same quarter a year earlier. That came with net income of $50M (1004% of revenue). For the full year FY2025, revenue was $3.5M (−67% year on year) and net income −$242M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 2, 2026On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development.Other event · Form 8-K
- Aug 6, 2026Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 6, 2026Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.